Apollo Therapeutics

Apollo Therapeutics is a Cambridge, United Kingdom-based biopharmaceutical company with additional operations in Massachusetts that translates early-stage academic research into clinical-stage medical treatments for oncology, inflammatory disorders, and rare diseases. Operating a capital-efficient hub-and-spoke portfolio model, the firm acquires intellectual property from university researchers to advance over 20 distinct therapeutic programs through preclinical development. The organization has raised over $395 million in total venture funding, including a $226.5 million Series C financing round in late 2023 to accelerate its growing pipeline. Apollo generates returns by out-licensing its advanced assets to major pharmaceutical partners and is backed by prominent institutional investors such as Patient Square Capital and B Capital. The enterprise was founded in 2015 as a joint venture by AstraZeneca, GlaxoSmithKline, Johnson and Johnson, and the technology transfer offices of three major British universities.